Intelligent Medical Software - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The intelligent medical software market size was valued at USD 4.47 billion in 2025 and is estimated to grow from USD 5.21 billion in 2026 to reach USD 11.26 billion by 2031, at a CAGR of 16.64% during the forecast period (2026-2031). This report is Segmented by Software Function (Diagnostic, Therapeutic, CDS, Monitoring, Workflow, Research), Technology (ML, Deep Learning, NLP, Computer Vision, Generative AI), Clinical Specialty (Radiology, Cardiology, Oncology, Neurology, Pathology, Others), Deployment (Cloud, On-Premises, Hybrid), End User (Hospitals, Diagnostic Labs, Ambulatory, Others), and Geography. Forecasts in Value (USD).

Global Intelligent Medical Software Market Trends and Insights

Clinical Documentation and Administrative Automation Demand

Clinical documentation accounted for 35-55% of a physician’s working day in hospital settings. Electronic health records added structure to medical records but did not eliminate this workload. Ambient AI scribing moved from early testing to enterprise deployment during 2025 and 2026. Oracle Health reported that its Clinical AI Agent saved more than 200,000 physician hours across U.S. deployments in a little over one year after launch, while Waystar reported USD 15.5 billion in prevented revenue-cycle denials and a 90% reduction in denial-management time through its AltitudeAI capabilities. As clinical notes became more structured and machine-readable, the intelligent medical software market benefited from better training data for diagnostic and prognostic applications.

Multimodal Healthcare Data Expansion

Clinical AI shifted from single-data-source pattern recognition to models that combined imaging, genomics, electronic health record time series, and pathology slides. The CLIMB dataset contained 19.01 terabytes of data and 4.51 million patient samples across 2D imaging, 3D video, time series, and molecular graphs. Its 2025 study found that multitask pretraining on varied clinical data improved performance on understudied modalities by up to 29%. Tempus AI presented a multimodal foundation model initiative based on more than 500 petabytes of molecularly grounded data, 45 million de-identified patient journeys, and more than 400,000 oncology records with genomic, transcriptomic, and imaging coverage. However, linked, time-stamped, consented, and well-annotated data remained difficult to assemble, making hospital partnerships as important as computing capacity for vendors in the intelligent medical software market.

Cybersecurity, Privacy and Data-Integrity Exposure

Healthcare remains a major target for cyberattacks. In December 2024, the U.S. Department of Health and Human Services proposed an update to the HIPAA Security Rule, requiring health care organizations to maintain technology asset inventories that identify AI software handling electronic protected health information. These requirements increase the need for audit-ready product design, stronger vendor oversight, and early integration of security controls in the intelligent medical software market. Federated learning and on-premises inference may gain traction as providers seek to keep patient health information within controlled systems, influencing cloud and hybrid deployment architectures, patient-data processing workflows, and system controls.

Other drivers and restraints analyzed in the detailed report include:

• Shortage of Clinicians and Diagnostic Specialists
• Regulatory and Reimbursement Maturation for AI-Enabled SaMD
• Clinical Validation and Generalizability Across Populations

Segment Analysis

Diagnostic and Screening Software held 33.22% revenue share in 2025. Radiology, pathology, and ophthalmology departments have long used imaging and pathology AI, supported by structured DICOM data, defined endpoints, and prior regulatory experience. The FDA authorized 295 AI-enabled medical devices in 2025, with radiology accounting for 73%. High procedural volumes and existing hospital workflow integration supported the intelligent medical software market size for diagnostic tools.

Therapeutic and Treatment-Planning Software is forecast to grow at a 20.93% CAGR through 2031. AI-guided radiotherapy target delineation, personalized drug dosing, and surgical navigation are supporting adoption. GE HealthCare received FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0 in June 2026 for radiation oncology planning. Clinical Decision Support Software can expand through EHR integration, while workflow software benefits from ambient scribing and revenue-cycle automation. Tempus AI reported USD 1.1 billion in total contract value for its data agreements in December 2025.

Machine Learning and Predictive Models held 56.23% revenue share in 2025. Validated use in diagnostic imaging, risk stratification, and population health management supported this installed base. Health systems are adding retraining and feedback processes to production workflows. Generative AI and Large Language Models is the fastest-growing technology category through 2031, while deep learning, computer vision, and natural language processing remain essential across radiology, pathology, surgical robotics, documentation, coding, and prior authorization.

A June 2026 npj Digital Medicine paper introduced AI4Doc-LLM for medical-record understanding, clinical decision support, and documentation generation. A 2026 Nature publication evaluated MIRA on selected electronic medical record tasks in a sandboxed environment. Both publications increased provider interest in agent-based workflows. These systems still require human oversight, clear clinical validation, and usable regulatory pathways. The intelligent medical software market will retain established machine-learning tools while generative applications enter defined clinical roles.

Complete Report Scope:

• By Software Function
  • Diagnostic and Screening Software
  • Therapeutic and Treatment-Planning Software
  • Clinical Decision Support Software
  • Monitoring and Predictive Analytics Software
  • Workflow, Documentation and Revenue-Cycle Software
  • Research and Life-Sciences Software
• By Technology
  • Machine Learning and Predictive Models
  • Deep Learning and Neural Networks
  • Natural Language Processing
  • Computer Vision
  • Generative AI and Large Language Models
• By Clinical Specialty
  • Radiology and Medical Imaging
  • Cardiology and Vascular Medicine
  • Oncology
  • Neurology and Neurosurgery
  • Pathology and Laboratory Medicine
  • Ophthalmology
  • Women's Health and Obstetrics
  • Other Clinical Specialties
• By Deployment
  • Cloud-Based
  • On-Premises
  • Hybrid
• By End User
  • Hospitals and Health Systems
  • Ambulatory Surgical Centers and Physician Groups
  • Diagnostic Laboratories and Imaging Centers
  • Specialty Clinics
  • Home Healthcare Providers
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held a 41.76% revenue share in 2025. The United States has a large base of digitized health records and cleared AI-enabled medical devices, supporting development, validation, and implementation. Canada finalized premarket guidance for machine-learning-enabled medical devices in April 2026, while Canadian health systems selected Oracle Health’s Clinical AI Agent for documentation pilots.

Europe is the second-largest regional market, led by Germany, the United Kingdom, and France. The EU AI Act places high-risk obligations on AI embedded in Class IIa and higher medical devices, with staged requirements running through August 2027. These rules raised compliance costs and favored vendors with CE-marked portfolios and established quality systems, while Germany’s Bundesnetzagentur and BfDI issued a joint compliance roadmap in July 2026.

Asia-Pacific is projected to grow at a 19.56% CAGR through 2031. China, India, Japan, South Korea, and Australia followed different investment and regulatory paths. South Korea’s Digital Medical Products Act took effect in January 2025, and a generative-AI medical device was approved there in April 2026. China is expanding radiology analytics in tier-one hospitals, while Japan’s PMDA DASH for SaMD2 program supports post-market update mechanisms. The Middle East and Africa and South America are smaller but strategic, supported by public investment, centralized UAE approval from January 2025, Brazil’s July 2026 WHO status, and South Africa’s September 2025 communication.

List of Companies Covered in this Report:

• Abbott Laboratories
• Aidoc Medical Ltd.
• Butterfly Network, Inc.
• Dassault Systemes
• DeepHealth, Inc.
• Epic Systems
• Roche
• GE HealthCare Technologies Inc.
• Health Catalyst, Inc.
• HeartFlow, Inc.
• Hologic
• IBM
• Intuitive Surgical, Inc.
• IQVIA
• Koninklijke Philips
• Mckesson
• Medtronic
• Merative, Inc.
• Microsoft
• NVIDIA
• Optum
• Oracle
• Qure.ai Technologies Private Limited
• RadNet, Inc.
• Siemens Healthineers
• Tempus AI, Inc.
• Veeva Systems
• Veradigm Inc.
• Viz.ai, Inc.
• Waystar Holding Corp.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support